You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Self-Supervised Training in Geospatial Applications with a Robust Hierarchical Vision Transformer (STAR)

    SBC: UNIVERSITY TECHNICAL SERVICES INC            Topic: OSD22A001

    Satellite Imagery in Geospatial Intelligence (GEOINT), in conjunction with imagery intelligence (IMINT), geospatial information, and other means of gaining intelligence, has greatly improved the potential of the warfighter and decision makers enabling them to gain a more comprehensive perspective, an in-depth understanding, and a cross-functional awareness of the operational environment. The Artif ...

    STTR Phase I 2022 Department of DefenseNational Geospatial-Intelligence Agency
  2. Spray-based visual indicator of opioids for the rapid and effective decontamination of large areas

    SBC: Triton Systems, Inc.            Topic: CBD20AT001

    Triton Systems, Inc. will collaborate with The University of Massachusetts Lowell to develop a spray-based technology for the rapid, visual identification of opioids, turning contaminated areas from nondescript white powders to a brightly colored spots for easy recognition with the naked eye. The technology leverages molecular recognition units that bind strongly and specifically to a variety of o ...

    STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense
  3. Eye-readable Solution-based Dye Displacement Probe for Large-area Detection of Opioids

    SBC: Intelligent Optical Systems, Inc.            Topic: CBD20AT001

    Intelligent Optical Systems, Inc., in collaboration with Bowling Green State University, proposes to develop a field-rugged, eye-readable indicating spray solution that can immediately detect synthetic opioids over a large area of contamination (i.e., military vehicles, individual protective equipment, clandestine labs, etc.). The proposed chemosensor in a spray solution format will detect multipl ...

    STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense
  4. Opioid Indicator Spray for Complex Surfaces

    SBC: Clear Scientific, LLC            Topic: CBD20AT001

    Opioids, especially synthetic opioids, are a constant threat to the safety of civilian first responders; there are now serious concerns about their use in modern chemical warfare. Fentanyl and its many analogues (carfentanil, remifentanil, lofentanil, mefentanil, sufentanil, etc.) are extremely hazardous—if ingested or inhaled, many synthetic opioids cause lethal intoxication with only a few gra ...

    STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense
  5. Low-shot Automated Performance Prediction via Transfer Learning

    SBC: Etegent Technologies, Ltd.            Topic: NGA20C001

    Low-shot objection recognition has become an area of active research in recent years, with advances dramatically improving performance when only a few samples are available, nominally fewer than 20. These technologies are a focus of the intelligence community (IC) because this challenge pertains to many intelligence problems, e.g., objects of interest are rare due to their use, sensitive nature, ...

    STTR Phase I 2021 Department of DefenseNational Geospatial-Intelligence Agency
  6. Development of selective calpain-1 inhibitors for chronic pain

    SBC: 1910 GENETICS INC.            Topic: 105

    PROJECT SUMMARY Never in the history of the United States has the unmet medical need to develop novel, non-opioid therapeutics for chronic pain been more urgent than it is today. More than 65 million US adults suffer from chronic pain, resulting in almost $635 billion in annual healthcare costs. Despite their limited efficacy, and potential for addiction, tolerance, and impaired motor performance, ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Therapeutic Monoclonal Antibody Against EGFL6, a Mediator of Tumor Growth and Metastasis

    SBC: Tradewind BioScience            Topic: 102

    SUMMARY A diagnosis of ovarian cancer (OvCa) is especially devastating. With 22,240 diagnoses in 2018 and an estimated 14,070 deaths, OvCa has the third-highest mortality rate, leading to the fifth-highest number of cancer deaths among women in the United States. The objective of this research is to validate the anti-tumor function of humanized antibodies with the end goal of identifying and devel ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. VAL-0914 Decreases PAO to Protect Against Cardiac Proteinopathies

    SBC: Enable Therapeutics LLC            Topic: NHLBI

    PROJECT SUMMARY Soluble pre-amyloid oligomers (PAO) are the most potent mediators of cytotoxicity, despite common focus on autophagy as a means to clear larger misfolded protein aggregates. Specifically, PAO, rather than aggresomes, are most correlated with desmin-related cardiomyopathy (DRC) caused by an Arg120Gly missense mutation of αB-Crystallin (CryABR120G). In addition to causing DRC, emerg ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Multi-stable Compliant-Mechanism-based Mattress for Bedsore Prevention

    SBC: K MEDICAL, LLC            Topic: NINR

    Abstract Pressure ulcers or decubitus ulcers, more commonly known as bedsores are a huge problem affecting 2.5 million patients every year in the US and causes 60,000 deaths every year. Pressures exceeding 32 mm of Hg in the bony prominences in the back of the patient body lead to bedsores. Despite the existing low air loss mattresses, alternating pressure mattresses and the state-of-the-art air f ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer

    SBC: Up Therapeutics LLC            Topic: 102

    Quadruple negative breast cancer (QNBC), lacking the expression of ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2) and AR (androgen receptor), is the breast cancer subtype with the worst prognosis, and QNBC disproportionately afflicts African Americans. It has no standard-of-care treatment targets and thus efficacious and safe treatments must be ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government